Onco Actu du 16 janvier 2018

	3.1 Prévention - Tabac
Funding cuts mean stop smoking services can’t offer support [Cancer Research UK] Figures from Cancer Research UK and Action on Smoking and Health (ASH) show half of local authorities cut budgets for Stop Smoking Services in 2017.
	3.7 Prévention - Alcool
Thangam Debbonaire: ‘The moment I saw the light about alcohol and cancer’ [The Guardian] Her new-found knowledge about alcohol’s potential toxicity has also unleashed an almost missionary zeal to raise awareness about its role as a cause of cancer, using her platform at Westminster.
	3.8 Prévention - Alimentation
Broadcast regulations aren’t enough to protect kids from TV junk food ads [Cancer Research UK] Our study looks at one set of young people at one time. This means that we cannot say adverts cause children to eat junk food. But our findings follow previous research in pointing to a link between TV ads and what children eat.
	4.2 Dép., diag. & prono. - Génome
Just Released – Our New Clinical NGS Process Report [enlightenbio] This new report details the observations and learnings across the complex, multi-step informatics aspects following clinical NGS sample preparation and sequencing, and which includes data analysis, knowledge extraction, and clinical reporting of actionable findings.
For Now, Sequencing Cancer Tumors Holds More Promise Than Proof [NPR] At Hopkins, the genomic tests usually don't offer any suggestion for treatment. Only about one quarter of patients at Hopkins are steered toward particular drugs or toward ongoing clinical trials. Other top medical centers find they can identify potential treatments only about 10 percent of the time.
	4.5 Dép., diag. & prono. - Colorectal
NHS bowel scope uptake boosted by a fifth when patients sent reassuring reminders [Cancer Research UK] The researchers found that the main concerns about the test included embarrassment, pain and fear of harm to the bowel. The leaflet, created by the researchers from University College London with help from the public, included patient testimonials and advice from a named and pictured local GP to address this.
	5.1 Traitements - Pré-clinique
Biologists’ new peptide could fight many cancers [MIT News] The new peptide targets a protein called Mcl-1, which helps cancer cells avoid the cellular suicide that is usually induced by DNA damage. By blocking Mcl-1, the peptide can force cancer cells to undergo programmed cell death.
Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos [EndPoints] A Genmab-sponsored study touts preclinical evidence that one of its targeted antibody-drug conjugates can be effective against a specific type of melanoma where existing treatment is failing, pointing to a potential new triple combination strategy.
	5.12 Immunothérapies
Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return [FiercePharma] Keytruda topped placebo at fending off cancer's return after surgery, an interim analysis of the Keynote-054 trial showed. The details of that spread weren't spelled out, though Merck said Keytruda prolonged recurrence-free survival "significantly longer" than placebo did.
	5.12.7 Immunothérapies - vaccins
Google backs $27M launch round for Holy Grail R&D work on two targets: a cancer vaccine and a universal flu jab [EndPoints] Vaccitech is launching a Phase II study to see if its cancer vaccine targeting the common 5T4 antigen can — in combination with a PD-1 checkpoint inhibitor — mount a more effective attack on prostate cancer cells. And if it works there, there’s a long lineup of cancers that it could be used against.
	5.12.8 Immunothérapies - Economie
SMC bars four medicines from NHS [PharmaTimes] The Scottish Medicines Consortium has rejecting NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro.
	5.2.1 Pharma - Partenariats
Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology [Syapse] Syapse and Roche will work jointly to develop software products and analytics solutions that empower healthcare providers with the tools and insights they need to practice precision medicine at scale, with the goal of improving patient outcomes and health-related quality of life.
	5.3.4 Traitements - AMM (FDA, EMA)
US expands scope of BI’s lung cancer drug Gilotrif [PharmaTimes] The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I, which can be detected by an approved test to determine whether patients are suitable for treatment.
	5.5 ASCO
Ipsen announces 13 posters and 1 oral presentation at the 2018 ASCO Gastrointestinal Symposium [Ipsen] Ipsen today announced that irinotecan liposome injection (Onivyde®), cabozantinib (Cabometyx®), lanreotide (Somatuline® Autogel® / Depot®), and telotristat ethyl (Xermelo®) are the subject of 11 posters, along with 2 others focusing on patients living with neuroendocrine tumors.
	6.10 Politiques
Government should offer assurances of post-Brexit medical radioisotopes supply [Parliament UK] The European Commission warns that the supply of medical radioisotopes is becoming more fragile and requires a more coordinated approach. The European Scrutiny Committee seeks assurance from the Government and an explanation of how the UK will develop its own policy.
	6.6 Publications
The Next Generation of Discovery – Dimensions [Digital Science] “Dimensions brings together funding data, publications, altmetrics, citations, clinical trials and patents in a richly linked discovery platform. But, that on its own is just the beginning.”
South Korean universities reach agreement with Elsevier after long standoff [Science] The agreement, which includes price hikes between 3.5% and 3.9%, was concluded shortly before 12 January, the day Elsevier had threatened to cut access to ScienceDirect.
A New Citation Database Launches Today: Digital Science’s Dimensions [The Scholarly Kitchen] An important innovation in a number of ways, Dimensions will offer stiff new competition for Elsevier and Clarivate.